Approximately 12-14% of the world’s population experiences peripheral arterial disease (PAD), a progressive atherosclerotic condition that can lead to serious complications such as ischemia, ulceration, and limb amputation if untreated. When lifestyle changes and medications fail, clinicians often use percutaneous transluminal angioplasty (PTA) —a minimally invasive procedure where a balloon, uncoated or coated with an antiproliferative drug (drug-coated balloon, DCB), is inflated at the occlusion site to restore blood flow. Although effective, restenosis and thrombosis limit PTA’s long-term success. DCBs directly address restenosis and indirectly address thrombosis by releasing an antiproliferative drug (e.g., Paclitaxel, PTX) to prevent neointimal hyperplasia and impede clot formation.